The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet its primary endpoint in patients with refractory chronic cough in Phase II trials.
The drug also failed to hit primary and secondary efficacy goals in a Phase II trial studying its use in treating pruritis in adults and adolescents with a history of atopic dermatitis earlier this year.